Fatigue on Wegovy® tablets

Fatigue in each tablet document

There is no single fatigue number for Wegovy® tablets, because each official source counts it in its own way. The US label summarises the 25 mg tablet study (Study 7, 204 adults, up to 64 weeks of treatment) in a paragraph rather than a table and says its common reactions resembled those of the 2.4 mg injection. ^[1] The trial was published as OASIS 4, and its abstract reports weight and digestive results but no fatigue figure; ^[4] the event counts were posted on ClinicalTrials.gov, ^[3] and the EU summary assigns a frequency band. ^[2]

Why 7.4% and “very common” can both be right

The two figures measure different things. The registry line counts one exact term, fatigue. Weakness (asthenia) does not appear in the record at all, which only tells you it stayed below the 5% listing threshold in both groups; the record does not say how many people reported it. ^[3] The EU band, by contrast, comes from a group of related terms, and unless stated otherwise its frequencies are taken from the four injection trials, with OASIS 4 described as having similar frequencies. ^[2] The US injection table likewise adds fatigue and asthenia together. ^[1]

So a reader who adds “tired” and “weak” together would expect a figure above 7.4%, and the documents do not contradict each other. What the tablet record does show clearly is the contrast with placebo: a single person in the placebo group reported fatigue. ^[3] That is a small number, and one more or one fewer case would move the placebo percentage noticeably, so the gap is best read as “clearly more common on the tablet” rather than as a precise ratio.

When tiredness tends to show up

The EU summary attaches its dose-escalation footnote to fatigue, and the tablet leaflet adds that the very common effects usually go away over time. ^[2] Neither document gives a duration. In the US label, the tablet starts at 1.5 mg for the first 30 days and moves through 4 mg and 9 mg to the 25 mg maintenance dose from day 91; if a step is not tolerated, the prescriber may delay it. ^[1] In the EU the same strengths change every four weeks, reaching 25 mg from week 13. ^[2]

Novo Nordisk’s tablet guide says side effects may be more noticeable when a new dose begins and that some people stay on one dose for longer than 30 days to give the body time to adjust; it also suggests keeping track of your dose and how you feel. ^[7] A log of when tiredness starts, set against the date of each step, is the most direct way to see your own pattern.

Label warnings that can feel like exhaustion

• Low blood sugar: the Medication Guide lists weakness, drowsiness, confusion, shakiness and sweating among its signs, mainly in type 2 diabetes with insulin or a sulfonylurea. ^[1] The tablet has not been studied for weight reduction in adults with type 2 diabetes (section 8.6). ^[1]
• Fluid loss after stomach upset: nausea and vomiting were very common with the tablet, ^[2] and the Medication Guide warns that losing fluids this way can lead to kidney problems and asks you to drink fluids. ^[1] MedlinePlus lists listlessness, dizziness and confusion among signs of severe dehydration. ^[8]
• Low blood pressure: the EU tablet table lists hypotension and orthostatic hypotension as uncommon. ^[2] In the US injection trials, which the label applies to both forms, blood-pressure-related reactions were reported in 1.3% against 0.4% on placebo, more often in people on blood pressure medicines. ^[1]
• A faster heart rate: with the tablet, resting pulse rose by 2 beats a minute on average, and 26.5% of tablet users against 20.8% on placebo had a rise of at least 20 beats at some point. ^[2] The Medication Guide asks you to report a racing or pounding heart that lasts several minutes. ^[1]
• Not explained: the documents describe fatigue as a reaction without proposing a mechanism. The registry also lists decreased appetite in 6.9% on the tablet against 1.0% on placebo, ^[3] but it does not say whether those were the same people who felt tired.

Common reasons for fatigue that are not the tablet

MedlinePlus lists anaemia and iron deficiency, depression or grief, sleep disorders such as insomnia and obstructive sleep apnoea, an underactive or overactive thyroid, alcohol, and medicines such as sedatives, antihistamines, blood pressure medicines and diuretics. It also names illnesses including diabetes, kidney or liver disease, heart failure, malnutrition and COVID-19. ^[5] COVID-19 was common in the tablet trial itself, recorded in 20.1% of tablet users and 17.6% on placebo. ^[3]

One interaction is specific to the semaglutide tablet. In a study with the tablet, levothyroxine exposure rose by 33%, and the US label asks for monitoring of oral medicines taken alongside Wegovy®; the EU summary suggests checking thyroid levels in people on levothyroxine. ^[1][2] If you take thyroid medicine and feel different after starting, that is worth raising with your prescriber rather than adjusting anything yourself.

What general health sources suggest

MedlinePlus suggests enough sleep each night, a balanced diet with plenty of water through the day, regular exercise, relaxation such as yoga or meditation, a manageable schedule and avoiding alcohol, nicotine and drugs. It says stimulants, caffeine included, are not effective treatments for fatigue and can make it worse when they are stopped, and it asks you not to stop or change any medicine without talking to your provider first. ^[5]

For tablet mornings the label adds one practical limit: only plain water, up to 4 ounces, goes with the dose, and coffee, food and other medicines wait at least 30 minutes. ^[1][7] Cleveland Clinic advises talking to a provider when tiredness lasts more than a few days, makes daily activities hard, has no clear reason, comes on suddenly, or you are over 65. ^[9]

Wegovy® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.

When to get help